Cantor Fitzgerald Estimates ABOS FY2026 Earnings

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Free Report) - Equities research analysts at Cantor Fitzgerald issued their FY2026 earnings per share estimates for shares of Acumen Pharmaceuticals in a research note issued on Monday, June 9th. Cantor Fitzgerald analyst P. Stavropoulos anticipates that the company will earn ($1.21) per share for the year. The consensus estimate for Acumen Pharmaceuticals' current full-year earnings is ($1.56) per share.

Several other analysts also recently commented on the company. HC Wainwright cut their target price on Acumen Pharmaceuticals from $15.00 to $11.00 and set a "buy" rating on the stock in a research note on Friday, March 28th. UBS Group cut their target price on Acumen Pharmaceuticals from $6.00 to $4.00 and set a "buy" rating on the stock in a research note on Friday, March 28th.

Acumen Pharmaceuticals Stock Down 6.1%

ABOS traded down $0.07 during trading on Wednesday, hitting $1.07. 199,313 shares of the company's stock traded hands, compared to its average volume of 287,829. The company's 50 day simple moving average is $1.05 and its two-hundred day simple moving average is $1.38. The company has a current ratio of 10.43, a quick ratio of 10.43 and a debt-to-equity ratio of 0.14. Acumen Pharmaceuticals has a 12-month low of $0.86 and a 12-month high of $3.60. The stock has a market capitalization of $64.81 million, a price-to-earnings ratio of -0.78 and a beta of 0.05.

Acumen Pharmaceuticals (NASDAQ:ABOS - Get Free Report) last issued its earnings results on Tuesday, May 13th. The company reported ($0.48) EPS for the quarter, beating the consensus estimate of ($0.56) by $0.08. During the same period in the previous year, the company earned ($0.25) EPS.

Hedge Funds Weigh In On Acumen Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the company. Susquehanna Fundamental Investments LLC bought a new position in shares of Acumen Pharmaceuticals during the 4th quarter valued at $25,000. Clune & Associates LTD. bought a new position in shares of Acumen Pharmaceuticals during the 4th quarter valued at $28,000. Intech Investment Management LLC bought a new position in shares of Acumen Pharmaceuticals during the 4th quarter valued at $32,000. Tower Research Capital LLC TRC lifted its holdings in shares of Acumen Pharmaceuticals by 427.5% during the 4th quarter. Tower Research Capital LLC TRC now owns 20,624 shares of the company's stock valued at $35,000 after buying an additional 16,714 shares during the period. Finally, SG Americas Securities LLC lifted its holdings in shares of Acumen Pharmaceuticals by 44.2% during the 4th quarter. SG Americas Securities LLC now owns 25,631 shares of the company's stock valued at $44,000 after buying an additional 7,859 shares during the period. 71.01% of the stock is owned by institutional investors.

About Acumen Pharmaceuticals

Acumen Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers.